Chan O et al. The prognostic impact of FLT3 in NPM1-mutated AML: Co-occurrence of FLT3-ITD and FLT3-TKD confers poor outcomes. Blood 2022;140(Supplement 1):3435-7. Abstract
Daver NG et al. A Phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine or magrolimab for patients with CD123-positive acute myeloid leukemia (AML). ASCO 2023;Abstract TPS7073.
Daver NG et al. Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: Phase Ib results. J Clin Oncol 2023;[Online ahead of print]. Abstract
Daver NG et al. Broad activity for the pivekimab sunirine (PVEK, IMGN632), azacitidine, and venetoclax triplet in high-risk patients with relapsed/refractory acute myeloid leukemia (AML). ASH 2022;Abstract 62.
de Bottom S et al. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: A randomized phase 3 trial. Blood 2023;141(2):156-67. Abstract
de Bottom S et al. Updated efficacy and safety data from the AGILE study in patients with newly-diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine. ASCO 2023;Abstract 7012.
Erba HP et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandum-duplication-positive acute myeloid leukemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401(10388):1571-83. Abstract
Erba HP et al. Assessing eligibility for non-intensive chemotherapy (IC) randomized clinical trials (RCT) in patients (pts) with newly diagnosed (ND) AML from the Connect Myeloid Disease Registry. ASCO 2022;Abstract 7029.
Geissler K et al. Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized crossover phase 3 study of an oral hypomethylating agent DEC-C compared to IV decitabine. EHA 2022;Abstract P573.
Grenet J et al. Comparing outcomes between liposomal daunorubicin/cytarabine (CPX-351) and HMA+venetoclax as frontline therapy in acute myeloid leukemia. ASH 2021;Abstract 32.
Jahn E et al. Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia 2023;[Online ahead of print]. Abstract
Komrokji RS et al. Treatment patterns and outcomes of patients with lower-risk myelodysplastic syndromes in the Connect® Myeloid Disease Registry. ASH 2021;Abstract 3686.
Kubasch AS et al. Development of luspatercept to treat ineffective erythropoiesis. Blood Adv 2021;5(5):1565-75. Abstract
Platzbecker U et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): Interim analysis of a phase 3, open-label, randomised controlled trial. Lancet 2023;402(10399):373-85. Abstract
Ritchie EK et al. Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: Report of CALGB 361101. Blood Adv 2022;6(12):3812-20. Abstract
Roboz GJ et al. Oral azacitidine prolongs survival in patients with AML in remission independently of measurable residual disease status. Blood 2022;139(14):2145-55. Abstract
Savona M et al. Efficacy and safety of oral decitabine/cedazuridine (ASTX727) in the CMML subpopulation from phase 2 and ASCERTAIN phase 3 studies. EHA 2023;Abstract P735.
Savona MR et al. Prolonged survival in bi-allelic TP53-mutated (TP53mut) MDS subjects treated with oral decitabine/cedazuridine in the ASCERTAIN trial (ASTX727-02). ASH 2022;Abstract 854.
Scott BL et al. Treatment patterns and outcomes of patients with primary or secondary acute myeloid leukemia by type of site (academic or community/government): A CONNECT® Myeloid Registry study. Blood 2022;140(Supplement 1):8923-5. Abstract
Sekeres MA et al. Impact of transfusions and treatment choice on time spent in healthcare facilities for patients with myelodysplastic syndromes. Blood 2022;140(Supplement 1):9818-20. Abstract
Stahl M et al. An agenda to advance research in myelodysplastic syndromes: A TOP 10 priority list from the first international workshop in MDS. Blood Adv 2023;7(12):2709-14. Abstract
Stahl M et al. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Rev 2023;[Online ahead of print]. Abstract
Sugita M et al. Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia. Nat Commun 2022;13(1):2227. Abstract
Zeidan AM et al. Finding consistency in classifications of myeloid neoplasms: A perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia 2022;36(12):2939-46. Abstract
Zeidan AM et al. Prospective comparison of outcomes with azacytidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood 2022;140(3):285-9. Abstract